|
業務類別
|
Biotechnology |
|
業務概覽
|
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics. |
| 公司地址
| 5980 Horton Street, Suite 600, Emeryville, CA, USA, 94608 |
| 電話號碼
| +1 510 250-7800 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.omniab.com |
| 員工數量
| 89 |
| Mr. Kurt A. Gustafson |
Executive Vice President, Finance, Principal Accounting Officer and Chief Financial Officer |
美元 496.78K |
29/04/2026 |
| Mr. Charles S. Berkman |
Chief Legal Officer and Secretary |
美元 503.53K |
29/04/2026 |
| Mr. Matthew W. Foehr |
President, Chief Executive Officer and Director |
美元 620.87K |
29/04/2026 |
|
|
| Dr. Carolyn R. Bertozzi, PhD |
Independent Director |
29/04/2026 |
| Mr. John L. Higgins |
Chairman of the Board |
29/04/2026 |
| Mr. Steven Love |
Independent Director |
29/04/2026 |
| Mr. Steven C. Crouse |
Independent Director |
29/04/2026 |
| Dr. Philip J. Gotwals, PhD |
Independent Director |
29/04/2026 |
| Dr. Jennifer R. Cochran, PhD |
Independent Director |
29/04/2026 |
| Mr. Matthew W. Foehr |
President, Chief Executive Officer and Director |
29/04/2026 |
|
|
|
|
